ALBANY, N.Y., Sept. 14, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced two promotions within the company's senior management team. George Svokos, Senior Vice President and Chief Commercial Officer, has been promoted to Chief Operating Officer, and Lori M. Henderson, Senior Vice President, General Counsel and Secretary, has added the role of head of Corporate Business Development. They will continue to report to AMRI President and CEO William S. Marth.
AMRI's three business unit heads will report to Mr. Svokos and he will continue to lead the Active Pharmaceutical Ingredient (API) Manufacturing business for the present time. Ms. Henderson will continue to head up AMRI's legal, mergers and acquisitions and corporate affairs activities for the company's locations worldwide, which includes the United States, Europe and Asia.
"Aligning our leadership as we grow and move forward with our strategy to be the preeminent supplier of custom and complex end-to-end services to the pharmaceutical industry will ensure AMRI's success as a whole," says William S. Marth, President and CEO, AMRI. "Both George and Lori have made significant contributions to AMRI, each demonstrating a leadership and vision, while helping navigate the complex M&A environment as the company continues to expand organically and inorganically."
George Svokos joined Albany Molecular Research, Inc. in January 2014. After serving as Senior Vice President Sales and General Manager-API, he assumed responsibility as Chief Commercial Officer. Before AMRI, Mr. Svokos was with Teva Pharmaceuticals Industries Ltd., most recently as Senior Vice President, U.S. Technical Operations.
Lori M. Henderson joined AMRI in February 2011, and is responsible for leading all of AMRI's legal, mergers and acquisitions and corporate affairs activities for the company's locations worldwide, including the United States, Europe and Asia. Before joining AMRI, she served as general counsel, corporate secretary and chief administrative officer for Rand Worldwide, Inc.
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Solutions (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, hormones, cytotoxic compounds and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
SOURCE AMRI
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article